177 related articles for article (PubMed ID: 10565814)
1. Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats.
Junot C; Nicolet L; Ezan E; Gonzales MF; Menard J; Azizi M
J Pharmacol Exp Ther; 1999 Dec; 291(3):982-7. PubMed ID: 10565814
[TBL] [Abstract][Full Text] [Related]
2. Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production.
Azizi M; Junot C; Ezan E; Hallouin MC; Guyene T; Ménard J
J Mol Med (Berl); 2002 Aug; 80(8):492-8. PubMed ID: 12185449
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory action of the peptide AcSDKP on the proliferative state of hematopoietic stem cells in the presence of captopril but not lisinopril.
Chisi JE; Wdzieczak-Bakala J; Riches AC
Stem Cells; 1997; 15(6):455-60. PubMed ID: 9402658
[TBL] [Abstract][Full Text] [Related]
4. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.
Junot C; Gonzales MF; Ezan E; Cotton J; Vazeux G; Michaud A; Azizi M; Vassiliou S; Yiotakis A; Corvol P; Dive V
J Pharmacol Exp Ther; 2001 May; 297(2):606-11. PubMed ID: 11303049
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Junot C; Ezan E; Ménard J
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
[TBL] [Abstract][Full Text] [Related]
6. In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis.
Junot C; Menard J; Gonzales MF; Michaud A; Corvol P; Ezan E
J Pharmacol Exp Ther; 1999 Jun; 289(3):1257-61. PubMed ID: 10336514
[TBL] [Abstract][Full Text] [Related]
7. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.
Azizi M; Ezan E; Reny JL; Wdzieczak-Bakala J; Gerineau V; Ménard J
Hypertension; 1999 Mar; 33(3):879-86. PubMed ID: 10082503
[TBL] [Abstract][Full Text] [Related]
8. Catabolism of the hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro: a new insight into the physiological role of the angiotensin-I-converting enzyme N-active site.
Rousseau-Plasse A; Lenfant M; Potier P
Bioorg Med Chem; 1996 Jul; 4(7):1113-9. PubMed ID: 8831983
[TBL] [Abstract][Full Text] [Related]
9. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations.
Comte L; Lorgeot V; Volkov L; Allegraud A; Aldigier JC; Praloran V
Eur J Clin Invest; 1997 Sep; 27(9):788-90. PubMed ID: 9352252
[TBL] [Abstract][Full Text] [Related]
10. The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans.
Wuerzner G; Peyrard S; Blanchard A; Lalanne F; Azizi M
J Hypertens; 2009 Jul; 27(7):1404-9. PubMed ID: 19506528
[TBL] [Abstract][Full Text] [Related]
11. Myelopoiesis modulation by ACE hyperfunction in kinin B(1) receptor knockout mice: relationship with AcSDKP levels.
Oliveira CR; Paredes-Gamero EJ; Barbosa CM; Nascimento FD; Batista EC; Reis FC; Martins AH; Ferreira AT; Carmona AK; Pesquero JB; Tersariol IL; Araújo RC; Bincoletto C
Chem Biol Interact; 2010 Mar; 184(3):388-95. PubMed ID: 20096676
[TBL] [Abstract][Full Text] [Related]
12. Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo.
Rousseau-Plasse A; Wdzieczak-Bakala J; Lenfant M; Ezan E; Genet R; Robinson S; Briscoe T; Melville J; Riches A
Exp Hematol; 1998 Oct; 26(11):1074-9. PubMed ID: 9766448
[TBL] [Abstract][Full Text] [Related]
13. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis.
Windt WA; Prakash J; Kok RJ; Moolenaar F; Kluppel CA; de Zeeuw D; van Dokkum RP; Henning RH
J Renin Angiotensin Aldosterone Syst; 2004 Dec; 5(4):197-202. PubMed ID: 15803438
[TBL] [Abstract][Full Text] [Related]
14. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Michaud A; Williams TA; Chauvet MT; Corvol P
Mol Pharmacol; 1997 Jun; 51(6):1070-6. PubMed ID: 9187274
[TBL] [Abstract][Full Text] [Related]
15. Development of an enzyme immunoassay for a stable amidated analog of the hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro.
Junot C; Theodoro F; Thierry J; Clement G; Wdzieczak-Bakala J; Ezan E
J Immunoassay Immunochem; 2001; 22(1):15-31. PubMed ID: 11486817
[TBL] [Abstract][Full Text] [Related]
16. Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study.
Azizi M; Ménard J; Peyrard S; Lièvre M; Marre M; Chatellier G
Diabetes Care; 2006 Jun; 29(6):1331-6. PubMed ID: 16732017
[TBL] [Abstract][Full Text] [Related]
17. Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells.
Li J; Volkov L; Comte L; Herve P; Praloran V; Charbord P
Exp Hematol; 1997 Feb; 25(2):140-6. PubMed ID: 9015214
[TBL] [Abstract][Full Text] [Related]
18. Catabolism of the tetrapeptide N-Ac-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of hematopoietic stem cell (CFU-S) proliferation, following in vitro incubation with hematopoietic tissues from normal and leukemic mice.
Wdzieczak-Bakala J; Grillon C; Robinson S; Riches A; Carde P; Lenfant M
Bull Cancer; 1993 May; 80(5):391-6. PubMed ID: 8173192
[TBL] [Abstract][Full Text] [Related]
19. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
[TBL] [Abstract][Full Text] [Related]
20. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril.
Westendorp B; Schoemaker RG; van Gilst WH; van Veldhuisen DJ; Buikema H
Eur J Pharmacol; 2005 Dec; 527(1-3):141-9. PubMed ID: 16310764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
